Top

World Journal of Urology

Published in:

01-11-2015 | Original Article

¹⁸F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy

Authors: Henrik Kjölhede, Göran Ahlgren, Helen Almquist, Fredrik Liedberg, Kerstin Lyttkens, Thomas Ohlsson, Ola Bratt

Published in: World Journal of Urology | Issue 11/2015

Abstract

Purpose

Salvage radiotherapy (SRT) for biochemical recurrence (BCR) following radical prostatectomy (RP) should if possible be added at a prostate-specific antigen (PSA) level of <1–2 ng/mL. The value of positron emission tomography combined with computed tomography (PET/CT) at such low PSA values is not defined. The purpose was to determine what proportion of a well-defined cohort of hormone-naïve patients who were candidates for early salvage radiotherapy had ¹⁸F-choline PET/CT findings suggesting metastases.

Materials and methods

Patients with untreated BCR following RP, PSA <2 ng/mL, and Gleason score ≥7 or PSA doubling time ≤6 months underwent ¹⁸F-choline PET/CT. Focal choline uptake in lymph nodes or skeletal sites was recorded.

Results

PET/CT indicated metastases in 16 (28 %) of 58 patients. In five (9 %) patients, the scans suggested bone metastases, and in 11 (19 %) patients, the scans suggested regional lymph node metastases only. For patients with PSA levels <1.0 ng/mL, the PET/CT scans indicated metastatic recurrence in 25 %.

Conclusions

¹⁸F-choline PET/CT may be valuable for selecting patients with BCR following RP for SRT or experimental treatment of oligometastases, even at low PSA values.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137CrossRefPubMed

Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932–942PubMedCentralCrossRefPubMed

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169(2):517–523CrossRefPubMed

Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S et al (2012) Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. Eur Urol 62(5):768–774CrossRefPubMed

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479CrossRefPubMed

Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572–578CrossRefPubMed

Slovin SF, Wilton AS, Heller G, Scher HI (2005) Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11(24 Pt 1):8669–8673CrossRefPubMed

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041PubMedCentralCrossRefPubMed

King CR (2012) The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 84(1):104–111CrossRefPubMed

10.

Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S et al (2014) Early salvage radiotherapy following radical prostatectomy. Eur Urol 65(6):1034–1043CrossRefPubMed

11.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2014) 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 32(4):965–970CrossRefPubMed

12.

Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048CrossRefPubMed

13.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H et al (2007) 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99(6):1415–1420CrossRefPubMed

14.

Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V et al (2010) Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37(2):301–309CrossRefPubMed

15.

Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R et al (2014) Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-choline PET/CT scan before salvage radiation therapy? J Nucl Med 55(9):1424–1429CrossRefPubMed

16.

Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35(1):18–23CrossRefPubMed

17.

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100(4):786–793CrossRefPubMed

18.

Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52(2):423–429CrossRefPubMed

19.

Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L (2008) Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl Med Biol 35(2):255–260CrossRefPubMed

20.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2012) Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 110(10):1501–1506CrossRefPubMed

21.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597CrossRefPubMed

22.

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T et al (2013) Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 54(6):833–840CrossRefPubMed

23.

Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ et al (2013) 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 63(5):792–796CrossRefPubMed

24.

Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T et al (2014) Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)f/(11)c-choline positron emission tomography/computerized tomography. J Urol 192(1):103–111CrossRefPubMed

25.

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D et al (2014) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. doi:10.1016/j.eururo.2014.02.011

26.

Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol (Madr) 52(8):1622–1628CrossRef

Title: 18F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy
Authors: Henrik Kjölhede
Göran Ahlgren
Helen Almquist
Fredrik Liedberg
Kerstin Lyttkens
Thomas Ohlsson
Ola Bratt
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 11/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1547-y

At a glance: The STEP trials

Springer Medicine

¹⁸F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy

Abstract

Purpose

Materials and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2015

Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)

Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve?

Analysis of the impact of adherent perirenal fat on peri-operative outcomes of robotic partial nephrectomy

Which is better? Guy’s versus S.T.O.N.E. nephrolithometry scoring systems in predicting stone-free status post-percutaneous nephrolithotomy

Utilization of a novel valveless trocar system during robotic-assisted laparoscopic prostatectomy

β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection